Association between the Polymorphisms rs2070744, 4b/a and rs1799983 of the NOS3 Gene with Chronic Kidney Disease of Uncertain or Non-Traditional Etiology in Mexican Patients

Medicina (Kaunas). 2023 Apr 24;59(5):829. doi: 10.3390/medicina59050829.

Abstract

Background and Objectives: Chronic Kidney Disease of uncertain or non-traditional etiology (CKDnT) is a form of chronic kidney disease of undetermined etiology (CKDu) and is not associated with traditional risk factors. The aim of this study was to investigate the association of polymorphisms rs2070744, 4b/a and rs1799983 of the NOS3 gene with CKDnT in Mexican patients. Materials and Methods: We included 105 patients with CKDnT and 90 controls. Genotyping was performed by PCR-RFLP's, genotypic and allelic frequencies were determined and compared between the two groups using χ2 analysis, and differences were expressed as odd ratios with 95% confidence intervals (CI). Values of p < 0.05 were considered statistically significant. Results: Overall, 80% of patients were male. The rs1799983 polymorphism in NOS3 was found to be associated with CKDnT in the Mexican population (p = 0.006) (OR = 0.397; 95% CI, 0.192-0.817) under a dominant model. The genotype frequency was significantly different between the CKDnT and control groups (χ2 = 8.298, p = 0.016). Conclusions: The results of this study indicate that there is an association between the rs2070744 polymorphism and CKDnT in the Mexican population. This polymorphism can play an important role in the pathophysiology of CKDnT whenever there is previous endothelial dysfunction.

Keywords: chronic; genetic; nitric oxide synthase type III; polymorphism; renal insufficiency.

MeSH terms

  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease* / genetics
  • Genotype
  • Humans
  • Male
  • Nitric Oxide Synthase Type III / genetics
  • Polymorphism, Single Nucleotide* / genetics

Substances

  • Nitric Oxide Synthase Type III
  • NOS3 protein, human

Grants and funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.